SAN DIEGO, CA--(Marketwired - Feb 5, 2014) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is pleased to announce executive leadership changes that will foster the Company's continued evolution into an increasingly profitable, $1 Billion Start-up™.
Effective February 1, 2014, Quentin Blackford was promoted to the Executive Leadership Committee as Executive Vice President of Finance and Investor Relations. Blackford joined NuVasive in 2009, and with nearly 15 years of financial experience within medical device organizations, his effort and insight will be invaluable as NuVasive drives toward $1 billion and beyond in revenues with improved profitability.
The Company also announced the resignation of Craig Hunsaker, Senior Vice President of Global Human Resources, which will be effective March 31, 2014. Hunsaker will assist in the transition of his responsibilities to Mike Paolucci, who has been appointed Executive Vice President of Global Human Resources, effective immediately.
Mike Paolucci joins NuVasive from Life Technologies Corporation™, a global life sciences company with over $4 billion in revenue, which was recently acquired by Thermo Fisher Scientific. He brings more than 20 years of broad global human resources experience at the executive and board level that will be instrumental to NuVasive's evolution into a larger, global business. At Life Technologies, Paolucci was responsible for the global compensation and benefit programs that encompassed more than 10,000 employees in nearly 40 countries. He also served as a human resources business partner for various business segments and was responsible for the Company's human resources technology systems. Prior to Life Technologies, he served as Vice President in various human resources capacities at Hewlett-Packard and EDS Corporation, from 2000 to 2009.
Alex Lukianov, Chairman and Chief Executive Officer, said, "We are exceptionally grateful to Craig for all of his contributions during his tenure with NuVasive. I am thrilled to welcome both Quentin and Mike to the NuVasive Executive Committee. Their strong propensity for outstanding standards, steadfast focus, and wealth of experience in achieving excellent outcomes will be instrumental to our executive leadership team. I look forward to their contributions and have tremendous confidence in the team we have organized to help us achieve our market share taking strategy."
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.